Glioma Brain Tumours - E12513 - SensiScreen Glioma

Glioma Clinical Trial

Official title:

Sensitive Diagnosis, Prognosis and Treatment Planning on Open Platform of Glioma Brain Tumours - E12513 - SensiScreen Glioma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04539431
• Other study ID #: ICP_glioma_001
• Status: Recruiting
• Start date: January 7, 2022
• Est. completion date: December 31, 2022

Study information

• Verified date: January 2022
• Source: Ente Ospedaliero Cantonale, Bellinzona
• Contact: Milo Frattini, PhD
• Phone: + 41 (0)91 816 08 05
• Email: milo.frattini[@]eoc.ch
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Validation of a new platform for the molecular characterization of patients affected by glioma. The new platform includes a series of faster, less expensive real-time PCR methodologies that, in comparison to standard analyses (DS, MS-PCR), are also characterized by higher sensitivity and consequently can be able to identify mutations in ctDNA extracted from liquid biopsies as well. The development of these assays will allow the analysis of molecular markers alteration even in liquid biopsies, providing a less invasive sampling than tissue biopsies, a procedure that sometimes is characterized by side effects or that allow the collection of few tissues for the histological and molecular diagnosis.

This study will not interfere with the patients routine treatment pathway and there will be no deviation from the standard of care: the molecular characterization of the tissues will be performed according to the standard diagnostic routine using the currently approved methodologies. For the retrospective study, it will be used the left-over DNA. For the cohort, that includes the collection and the subsequent analysis of liquid biopsies (prospective study), blood and CSF will be sampled during surgery.

The mutations in the molecular markers will be analyzed in tissue as well as in plasma and CFS samples by the new real-time based assays. Then, the qualitative and quantitative values obtained on liquid biopsies with the new methodology will be compared to the results of the standard methodologies already obtained, for diagnostic routine, on surgical tissue samples of the same patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 220
• Est. completion date: December 31, 2022
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Retrospective Cohort

Inclusion Criteria:

• Patient with available tissue material or with available molecular data concerning the tissue biopsy obtained during surgery and analyzed for diagnosis

Exclusion Criteria:

• Insufficient amount of tumor cells in the tissue biopsy for the molecular characterization

• Inability to consent and follow the procedures of the study (for alive patients)

Prospective Cohort

Inclusion Criteria:

• Age = 18 years old

• Affected by suspected glioma and requiring surgery

• Patient with available tissue material or with available molecular data concerning the tissue biopsy obtained during surgery and analyzed for diagnosis

• Written informed consent

Exclusion Criteria:

• Insufficient amount of tumor cells in the tissue biopsy for the molecular characterization

• Inability to consent and follow the procedures of the study

• Women who are pregnant or breast feeding

Related Conditions & MeSH terms

• Glioma

Intervention

Genetic:
• validation of new technologies
Development of a new molecular assay on tissue as well as on liquid biopsies (plasma and CSF), based on a single, open, real-time PCR platform with unprecedented sensitivity

Locations

Country	Name	City	State
Switzerland	Institute of Pathology Ente Ospedaliero Cantonale	Locarno

Sponsors (3)

Lead Sponsor	Collaborator
Ente Ospedaliero Cantonale, Bellinzona	Istituto Cantonale di Patologia, Neurocenter of Southern Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Demonstration that the new methodology improves the features	Demostrate that are found at least the same number of mutations in comparison with respect to standard tests	2 hours